<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129311">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736176</url>
  </required_header>
  <id_info>
    <org_study_id>M12-920</org_study_id>
    <nct_id>NCT01736176</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel for the Treatment of Non-motor Symptoms in Subjects With Advanced Parkinson's Disease</brief_title>
  <official_title>An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate change in non-motor symptoms from
      baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess changes in non-motor symptoms using Non-Motor Symptom Scale</measure>
    <time_frame>Baseline compared to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who use health resources</measure>
    <time_frame>Baseline compared to Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Collect  use of health resources (emergency room, doctors, urgent care, hospitals) with the Health Resource Utilization Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who have Adverse Events</measure>
    <time_frame>Baseline compared to \ Week 60</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Collect number and type of safety events with adverse event collection, vitals, and labs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in non-motor symptoms using Non-Motor Symptom Scale</measure>
    <time_frame>Baseline compared to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in motor symptoms using United Parkinson's Disease Rating Scale</measure>
    <time_frame>Baseline compared to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess improvements in cognition using neurocognition assessments: Spatial Working Memory</measure>
    <time_frame>Baseline compared  to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in quality of life through: Parkinson's Disease Questionnaire-39 Item</measure>
    <time_frame>Baseline to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in quality of life through: Patient Global Impression of Change</measure>
    <time_frame>Baseline to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in quality of life through: Treatment Satisfaction Question</measure>
    <time_frame>Baseline to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in quality of life through: Health-Related Productivity Questionnaire</measure>
    <time_frame>Baseline to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in motor symptoms using Parkinson's Disease Diary</measure>
    <time_frame>Baseline compared to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Levodopa-Carbidopa Intestinal Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm, open label: Levodopa-Carbidopa Intestinal Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa-Carbidopa Intestinal Gel</intervention_name>
    <description>Dose levels will be individually optimized. Should be kept within a range of 0.5-10 ml/hour (10-200 mg levodopa/hour) and is usually 2-6 ml/hour (40-120 mg levodopa/hour).</description>
    <arm_group_label>Levodopa-Carbidopa Intestinal Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a diagnosis of idiopathic Parkinson's disease according to the
             United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria

          -  Demonstrate persistent motor fluctuations in spite of individually optimized
             treatment

          -  Subject must experience a minimum of 3 hours &quot;Off&quot; time

        Exclusion Criteria:

          -  Subject's PD diagnosis is unclear or there is a suspicion that the subject has a
             Parkinsonian syndrome such as secondary Parkinsonism (e.g., caused by drugs, toxins,
             infectious agents, vascular disease, trauma, brain neoplasm), Parkinson-plus syndrome
             (e.g., Multiple System Atrophy, Progressive Supranuclear Palsy, Diffuse Lewy Body
             Disease, Corticobasilar Degeneration), or other neurodegenerative disease that might
             mimic the symptoms of PD.

          -  Subject has undergone neurosurgery for the treatment of Parkinson's disease

          -  Subject for whom the placement of a PEG-J tube for LCIG treatment is contraindicated
             or is considered a high risk for the PEG-J procedure according to the
             gastroenterology evaluation (e.g., pathological changes of the gastric wall,
             inability to bring the gastric wall and abdominal wall together, blood coagulation
             disorders, peritonitis, acute pancreatitis, paralytic ileus).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet  Benesh, BS</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Willy  Cramer, MS</last_name>
    <email>wil.cramer@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle  Brueck, BS</last_name>
    <email>michelle.brueck@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 85176</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 85176</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 66684</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 66684</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 103155</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 103155</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 82634</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 82634</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 112857</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 112857</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 103156</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 103156</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 66682</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 66682</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 110115</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 110115</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 82635</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 82635</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84453</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 84453</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 89193</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 89193</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carbidopa</keyword>
  <keyword>levodopa</keyword>
  <keyword>Advanced Parkinson's disease</keyword>
  <keyword>Safety and efficacy</keyword>
  <keyword>levodopa-carbidopa intestinal gel,</keyword>
  <keyword>Non-Motor Symptom Scale</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
